{"id":781389,"date":"2023-08-31T10:53:57","date_gmt":"2023-08-31T14:53:57","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/"},"modified":"2023-08-31T10:53:57","modified_gmt":"2023-08-31T14:53:57","slug":"ultragenyx-to-participate-at-investor-conferences-in-september","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/","title":{"rendered":"Ultragenyx to Participate at Investor Conferences in September"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Citi BioPharma Conference on September 6 in Boston<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>Morgan Stanley Healthcare Conference on September 12 in New York City<\/em>\n      <\/p>\n<p>NOVATO, Calif., Aug.  31, 2023  (GLOBE NEWSWIRE) &#8212; Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company&#8217;s chief executive officer and president, will participate in a panel discussion at Citi\u2019s 18<sup>th<\/sup> Annual BioPharma Conference on Wednesday, September 6, 2023, at 8:50 a.m. EST and a fireside chat at the Morgan Stanley 21<sup>st<\/sup> Annual Global Healthcare Conference on Tuesday, September 12, 2023, at 8:50 a.m. EST.<\/p>\n<p>The live and archived webcast of the panel and fireside chat will be accessible from the company\u2019s website at https:\/\/ir.ultragenyx.com\/events-presentations.<\/p>\n<p>About Ultragenyx Pharmaceutical Inc.<\/p>\n<p>Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.<\/p>\n<p>The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx\u2019s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.<\/p>\n<p>For more information on Ultragenyx, please visit the company&#8217;s website at: www.ultragenyx.com.<\/p>\n<p>Contacts \u2013 Ultragenyx Pharmaceutical, Inc.<br \/>Investors<br \/>Joshua Higa <br \/>ir@ultragenyx.com<\/p>\n<p>Media<br \/>Jeff Blake <br \/>media@ultragenyx.com<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDA3NyM1NzkxNzkwIzIwMDkyOTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NjI0NmE4MTEtNzU2My00M2QxLTk4MjktM2YxMmEzZDE1Mzg5LTEwMjA4NjQ=\/tiny\/Ultragenyx-Pharmaceutical-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Citi BioPharma Conference on September 6 in Boston Morgan Stanley Healthcare Conference on September 12 in New York City NOVATO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) &#8212; Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company&#8217;s chief executive officer and president, will participate in a panel discussion at Citi\u2019s 18th Annual BioPharma Conference on Wednesday, September 6, 2023, at 8:50 a.m. EST and a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023, at 8:50 a.m. EST. The live and archived webcast of the panel and fireside chat &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ultragenyx to Participate at Investor Conferences in September&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781389","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ultragenyx to Participate at Investor Conferences in September - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ultragenyx to Participate at Investor Conferences in September - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Citi BioPharma Conference on September 6 in Boston Morgan Stanley Healthcare Conference on September 12 in New York City NOVATO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) &#8212; Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company&#8217;s chief executive officer and president, will participate in a panel discussion at Citi\u2019s 18th Annual BioPharma Conference on Wednesday, September 6, 2023, at 8:50 a.m. EST and a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023, at 8:50 a.m. EST. The live and archived webcast of the panel and fireside chat &hellip; Continue reading &quot;Ultragenyx to Participate at Investor Conferences in September&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-31T14:53:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDA3NyM1NzkxNzkwIzIwMDkyOTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-september\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-september\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ultragenyx to Participate at Investor Conferences in September\",\"datePublished\":\"2023-08-31T14:53:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-september\\\/\"},\"wordCount\":274,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNDA3NyM1NzkxNzkwIzIwMDkyOTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-september\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-september\\\/\",\"name\":\"Ultragenyx to Participate at Investor Conferences in September - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-september\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-september\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNDA3NyM1NzkxNzkwIzIwMDkyOTE=\",\"datePublished\":\"2023-08-31T14:53:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-september\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-september\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-september\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNDA3NyM1NzkxNzkwIzIwMDkyOTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNDA3NyM1NzkxNzkwIzIwMDkyOTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ultragenyx-to-participate-at-investor-conferences-in-september\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ultragenyx to Participate at Investor Conferences in September\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ultragenyx to Participate at Investor Conferences in September - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/","og_locale":"en_US","og_type":"article","og_title":"Ultragenyx to Participate at Investor Conferences in September - Market Newsdesk","og_description":"Citi BioPharma Conference on September 6 in Boston Morgan Stanley Healthcare Conference on September 12 in New York City NOVATO, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) &#8212; Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company&#8217;s chief executive officer and president, will participate in a panel discussion at Citi\u2019s 18th Annual BioPharma Conference on Wednesday, September 6, 2023, at 8:50 a.m. EST and a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday, September 12, 2023, at 8:50 a.m. EST. The live and archived webcast of the panel and fireside chat &hellip; Continue reading \"Ultragenyx to Participate at Investor Conferences in September\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/","og_site_name":"Market Newsdesk","article_published_time":"2023-08-31T14:53:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDA3NyM1NzkxNzkwIzIwMDkyOTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ultragenyx to Participate at Investor Conferences in September","datePublished":"2023-08-31T14:53:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/"},"wordCount":274,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDA3NyM1NzkxNzkwIzIwMDkyOTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/","name":"Ultragenyx to Participate at Investor Conferences in September - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDA3NyM1NzkxNzkwIzIwMDkyOTE=","datePublished":"2023-08-31T14:53:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDA3NyM1NzkxNzkwIzIwMDkyOTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNDA3NyM1NzkxNzkwIzIwMDkyOTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ultragenyx-to-participate-at-investor-conferences-in-september\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ultragenyx to Participate at Investor Conferences in September"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781389"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781389\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}